BACKGROUND: The optimal duration of antibiotic therapy for ventilator-associated tracheitis (VAT) has not been defined, which may result in unnecessarily prolonged courses of antibiotics. The primary objective of this study was to determine whether prolonged-course (≥7 days in duration) therapy for VAT was more protective against progression to hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP), compared with short-course antibiotics (<7 days in duration). The secondary objective was to determine whether prolonged-course therapy was more likely to result in the acquisition of multidrug-resistant organisms (MDROs) compared with short-course therapy. METHODS: We conducted a retrospective cohort study of children ≤18 years of age hospitalized in the intensive care unit and intubated for ≥48 h from January 2007 through December 2009 who received antibiotic therapy for VAT. RESULTS: Of the 1616 patients intubated for at least 48 h, 150 received antibiotics for clinician-suspected VAT, although only 118 of these patients met VAT criteria. Prolonged-course antibiotics were not protective against subsequent development of HAP or VAP (hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.40-2.91). Factors associated with subsequent MDRO colonization or infection included prolonged-course antibiotic therapy (HR, 5.15; 95% CI, 1.54-7.19), receipt of combination antibiotic therapy (HR, 3.24; 95% CI, 1.54-6.82), and days of hospital exposure prior to completing antibiotic therapy (HR, 1.08; 95% CI, 1.04-1.12). CONCLUSIONS: A prolonged course of antibiotics for VAT does not appear to protect against progression to HAP or VAP compared with short-course therapy. Furthermore, prolonged antibiotic courses were associated with a significantly increased risk of subsequent MDRO acquisition.
BACKGROUND: The optimal duration of antibiotic therapy for ventilator-associated tracheitis (VAT) has not been defined, which may result in unnecessarily prolonged courses of antibiotics. The primary objective of this study was to determine whether prolonged-course (≥7 days in duration) therapy for VAT was more protective against progression to hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP), compared with short-course antibiotics (<7 days in duration). The secondary objective was to determine whether prolonged-course therapy was more likely to result in the acquisition of multidrug-resistant organisms (MDROs) compared with short-course therapy. METHODS: We conducted a retrospective cohort study of children ≤18 years of age hospitalized in the intensive care unit and intubated for ≥48 h from January 2007 through December 2009 who received antibiotic therapy for VAT. RESULTS: Of the 1616 patients intubated for at least 48 h, 150 received antibiotics for clinician-suspected VAT, although only 118 of these patients met VAT criteria. Prolonged-course antibiotics were not protective against subsequent development of HAP or VAP (hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.40-2.91). Factors associated with subsequent MDRO colonization or infection included prolonged-course antibiotic therapy (HR, 5.15; 95% CI, 1.54-7.19), receipt of combination antibiotic therapy (HR, 3.24; 95% CI, 1.54-6.82), and days of hospital exposure prior to completing antibiotic therapy (HR, 1.08; 95% CI, 1.04-1.12). CONCLUSIONS: A prolonged course of antibiotics for VAT does not appear to protect against progression to HAP or VAP compared with short-course therapy. Furthermore, prolonged antibiotic courses were associated with a significantly increased risk of subsequent MDRO acquisition.
Authors: J L Trouillet; J Chastre; A Vuagnat; M L Joly-Guillou; D Combaux; M C Dombret; C Gibert Journal: Am J Respir Crit Care Med Date: 1998-02 Impact factor: 21.405
Authors: D C Bergmans; M J Bonten; C A Gaillard; F H van Tiel; S van der Geest; P W de Leeuw; E E Stobberingh Journal: J Antimicrob Chemother Date: 1997-04 Impact factor: 5.790
Authors: S Nseir; C Di Pompeo; P Pronnier; S Beague; T Onimus; F Saulnier; B Grandbastien; D Mathieu; M Delvallez-Roussel; A Durocher Journal: Eur Respir J Date: 2002-12 Impact factor: 16.671
Authors: Jennifer A Muszynski; James Sartori; Lisa Steele; Randall Frost; Wei Wang; Nadeem Khan; Anthony Lee; Ada Lin; Mark W Hall; Onsy Ayad Journal: Pediatr Crit Care Med Date: 2013-06 Impact factor: 3.624
Authors: Darunee Chotiprasitsakul; Jennifer H Han; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Anna T Conley; Pam Tolomeo; Jacqueleen Wise; Pranita D Tamma Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Daniel Drozdov; Stefanie Schwarz; Alexander Kutz; Eva Grolimund; Anna Christina Rast; Deborah Steiner; Katharina Regez; Ursula Schild; Merih Guglielmetti; Antoinette Conca; Barbara Reutlinger; Cornelia Ottiger; Florian Buchkremer; Sebastian Haubitz; Claudine Blum; Andreas Huber; Ulrich Buergi; Philipp Schuetz; Andreas Bock; Christoph Andreas Fux; Beat Mueller; Werner Christian Albrich Journal: BMC Med Date: 2015-05-01 Impact factor: 8.775
Authors: Dimitri M Drekonja; Barbara Trautner; Carla Amundson; Michael Kuskowski; James R Johnson Journal: JAMA Date: 2021-07-27 Impact factor: 157.335